Aster DM Quality Care Ltd Q2 FY2025 Concall Summary

Key Takeaways

• India business delivered a strong quarter: Revenue grew 16% YoY to INR 1,086 cr while operating EBITDA jumped 48% to INR 233 cr, with margins expanding over 450 bps to 21.4%.
• Margin expansion is structural, not seasonal: Material costs have fallen 500 bps over three years to 20.3% of revenue, and management sees another 100 bps of efficiency ahead, plus 200-300 bps from manpower leverage as brownfield beds fill.
• The bed pipeline is fully funded and margin-safe: Nearly 1,900 beds will be added over three years, overwhelmingly brownfield, with INR 1,250 cr of the INR 1,450 cr capex still to be spent across FY25-FY27.
• Labs turned profitable and pharmacy is next: Aster Labs hit 11% EBITDA margin in Q2, up from breakeven in Q4 FY24, while the wholesale pharmacy restructuring has already reduced EBITDA losses.
• What to watch next quarter: Whether the Andhra-Telangana cluster sustains its 15-16% EBITDA run-rate, the pace of the 100-bed Medcity ramp that opens this month, and any clarity on M&A or platform discussions.

Margin Expansion: Drivers and Sustainability

• Material cost efficiency is the biggest lever: Material cost as a percentage of revenue (excluding wholesale pharmacy) has dropped from 25.3% in FY22 to 20.3% in Q2 FY25, a 500 bps improvement driven by procurement compliance and consolidation. Management sees another 100 bps potential in coming years.
• Manpower cost benefits from brownfield math: New brownfield beds require only bedside staff, not leadership or administrative hires, creating 200-300 bps of additional manpower leverage as those beds ramp up. Overheads have already improved 100 bps with another 50-100 bps possible.
• Mature hospitals anchor the portfolio: Hospitals operating over six years, representing 72% of the hospital segment, delivered 25.9% EBITDA margins in Q2 with a 32.4% ROCE, up over 530 bps YoY.
• Q2 is seasonally the strongest quarter, but 24% is sustainable: Q1 is weakest due to Ramadan and school holidays, while Q3 and Q4 are not expected to see major downfalls. Strong October occupancy supports the outlook.

Sunil Kumar: "Yes, it's sustainable. Because we are talking about only 24, not like I've not achieved just yet 30."

Cluster Performance

• Karnataka has higher margin potential than Kerala: Karnataka ARPOB runs INR 58,000-60,000 versus Kerala's ~INR 40,000 average, while nurse wages are INR 18,000-20,000 versus INR 30,000-32,000 in Kerala. Management sees Karnataka reaching 29-30% margins, 300-400 bps above Kerala's ceiling.
• Kerala occupancy can stretch beyond the 75-80% sweet spot: Management can manage closer to 90% through operational efficiency and by balancing scheme versus cash patients. Q2 occupancy dipped slightly due to festive seasonality, with a surge expected in coming days.
• Andhra-Telangana turnaround is gaining traction: The cluster had been stuck at 10-11% EBITDA and ~50% occupancy. Q2 EBITDA reached 15-16%, and management targets above 20% in the next two to three years, calling it achievable and sustainable.

Sunil Kumar: "With even the small increase in the top line, we're able to see a big movement in the EBITDA margin."

ARPOB and Payor Mix

• ARPOB grew 12% YoY in H1, driven by multiple levers: Price increases contributed 3-3.5%, revenue assurance from IT consolidation (HIS, ERP, service/item master) added ~1%, ALOS reduction of 6% YoY improved bed turnover, and a shift away from lower-paying scheme patients lifted the mix.
• Insurance penetration rose over 300 bps to 30% of payor mix: Cash patients grew 20%, TPA grew 30%, while scheme patients declined 11-12%. At Calicut, scheme mix fell 300-400 bps; at Medcity, ~400 bps.
• Insurance ARPOB is not dilutive: Management stated that IP ARPOB for cash versus TPA shows hardly a single-digit discount, insurance patients tend to choose higher case-mix procedures and twin-sharing or single rooms, and renewals every two years capture over 10% inflation offset.
• Medium-term ARPOB growth expectation is 7-8% over a three-to-four-year span, supported by case-mix improvement, bed-mix shifts, and periodic price increases.

Capacity Expansion

• 1,900 beds targeted over three years, majority brownfield: Brownfield additions avoid the margin dilution of greenfield projects. Key brownfield targets: Aster Medcity to ~950 beds, Aster CMI to ~850 beds, Aster Whitefield to ~500 beds.
• Greenfield project in Hyderabad: A 300-bed specialized women and children hospital, signed under a 30-31 year lease on a warm-shell building, expected to complete by FY26. Management claims it will be the biggest such facility in Hyderabad.
• Aster CMI adding 350 beds under a 20-year lease: This and the Hyderabad lease drove the increase in ROU assets and lease liabilities this quarter. Rental cost at stabilized occupancy is expected at 4-5% of revenue.
• Near-term openings: 100 beds at MIMS Kannur already operationalized; 100 beds at Aster Medcity Kochi received occupancy certificate and open this month; Whitefield 150-bed brownfield expansion expected operational this year or later part.
• Calicut and Trivandrum expansions planned but no specific timelines were provided.

Sunil Kumar: "We have operationalized 100 beds in MIMS Kannur during the quarter and over the next three years, we aim to further add nearly 1,900 beds, with the majority of these being brownfield expansion to ensure that there is not much dilution in our margins."

Labs, Pharmacy, and Adjacent Businesses

• Aster Labs reached 11% EBITDA margin in Q2: The business hit breakeven in Q4 FY24, improved to 3.4% in Q1 FY25, and jumped to 11% in Q2. External (non-Aster) business grew 41% YoY, and the target is to move that mix from 28% to near 50% in two to three years, which would lift margins above 20%.
• Wholesale pharmacy restructuring improved India EBITDA: The BU2 back-end purchasing operation was outsourced six months ago because it was not creating operating leverage. This reduced reported revenue but also reduced EBITDA losses. BU1 (B2B/B2C trade) continues growing at 10% YoY. Pharmacy breakeven is expected sometime near FY26.
• Labs require no additional processing infrastructure: Future investment is limited to collection centers and home-care capabilities via the upcoming app.
• O&M business remains a wait-and-watch: The asset-light model delivers lower ARPOBs and margins but double-digit ROCE. Challenges in tier-2 and tier-3 cities include clinician retention and limited high-end case mix. Management wants to stabilize current units before expanding further.

Sunil Kumar: "We want to stabilize this one before we look at expanding further."

Strategy, Leadership, and Capital Allocation

• Family members have taken defined regional roles post-segregation: Anoop Moopen focuses on the Kerala cluster and project expansion; Dr. Zeba Azad Moopen focuses on Karnataka cluster and medical strategy. Both have joined the board along with two independent directors.
• CEO hiring is deferred: Management stated the current team is capable of delivering this year's commitments and will revisit the decision over the next few quarters, with timing potentially dependent on transactions being explored.
• M&A and platform discussions are ongoing: The stated objective is to take a leadership position in South India, where Aster is already the second-largest player. Opportunities in Maharashtra and Tamil Nadu are being explored, but management offered no commitments. More clarity is expected in the next couple of quarters.
• Promoter pledge is being restructured: The pledge, taken as a bridge loan during the segregation transaction, has been reduced significantly and is being refinanced. Restructuring is expected by year-end.
• Consolidated ROCE improved 390 bps YoY to 18%: The hospital and clinic segment ROCE rose to 23.8% from 20.1%, with mature hospitals reaching 32.4%.

Alisha Moopen: "We would look at maybe a CEO in the future. Right now, we seem to be scaling up quite well... We believe that the team at hand is more than capable of delivering what we've committed to for this year and we will relook at this maybe over the next a few quarters."

Guidance & Commitments

Key Metrics